Personalis Inc (PSNL) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Personalis Inc $1.83, price $16.28, upside -88.8%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Personalis Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.9300 – $26.05 · fair‑value band $1.21 – $2.28 · the $16.28 price screens above the $1.83 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Personalis in your weekly email
Every Wednesday you see whether Personalis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Show more
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Stock analysis
Personalis Inc (PSNL) currently trades at $16.28, while our model-based Fair Value estimate is $1.83, 88.8% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $1.21 (bear) to $2.28 (bull), the price of $16.28 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Personalis Inc reported revenue of $69.6M in FY2025 versus $85.5M in FY2021, a compound −5.0%/yr. Reported net income was −$81.3M in FY2025.
Key figures
Market cap $1.7B · P/S ratio 25.1 · EPS (TTM) $−1.10 · Net margin −117% · Return on equity −50.3% · Return on assets (EBIT) −31.3% · Operating margin −150% · Revenue (TTM) $69.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 11% below its 52-week high and 223% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −89%, PSNL screens richer than that median.
Fair Value models
Bear $1.21Fair Value $1.83Bull $2.28
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−17.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.4%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.5%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−53.6% (2020) → −126.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 136 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score34 · Bottom 25%
Fair Value upside−88.7% · Bottom 25%
Profitability
Return on assets−25.0% · Bottom 25%
Net margin (TTM)−153.8% · Bottom 25%
Operating margin (TTM)−150.3% · Bottom 25%
Growth and dividend
Revenue growth30.0% · Top 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B6.53× · Priciest 25%
P/S (TTM)24.47× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 28
PAST (return on equity)0· sector 10
HEALTH (low debt)100· sector 93
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Personalis Inc Fair Value". https://www.fairvalue-calculator.com/stock/PSNL
Frequently asked questions
Is Personalis Inc (PSNL) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $1.83 versus a price of $16.28, about −89% upside (overvalued).
What is the fair value of PSNL?
Our model-based fair value for Personalis Inc is $1.83 (as of Sep 24, 2026), built from audited fundamentals. The current price: $16.28.
What is the quality score of PSNL?
Personalis Inc has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Personalis Inc (PSNL)?
Our model-based price target is the fair value of $1.83 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $1.21, optimistic scenario $2.28. It is a calculation from audited fundamentals, not an analyst target.
What is the Personalis Inc stock forecast for 2026?
Our models put fair value at $1.83, about −89% upside versus a price of $16.28 (overvalued). Cautious scenario $1.21, optimistic scenario $2.28. The calculation is refreshed regularly with new filings.
What is the revenue of Personalis Inc (PSNL)?
Personalis Inc reported trailing-twelve-month revenue of about $69.7M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Personalis Inc (PSNL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Personalis Inc it is $1.83 per share (as of Sep 24, 2026), against a price of $16.28. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Personalis Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, PSNL trades above its calculated fair value: price $16.28, fair value $1.83, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PSNL?
No. The price is what the market pays today ($16.28); the fair value is what the company's own numbers justify ($1.83). For Personalis Inc the two are $14.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is Personalis Inc worth?
The market values Personalis Inc at about $1.7B (market capitalisation, as of Sep 24, 2026). Per share that is $16.28; our models calculate a fair value of $1.83 per share.
What do the bullish and bearish scenarios say about PSNL?
Our models span a range for Personalis Inc: cautious scenario $1.21, base $1.83, optimistic $2.28 per share (as of Sep 24, 2026, price $16.28). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Personalis Inc (PSNL)?
Balance-sheet figures for Personalis Inc (as of Sep 24, 2026): return on equity −50.3%, debt of 0.00 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is PSNL from its 52-week high?
Personalis Inc trades at $16.28, about 11% below its 52-week high of $18.38 and 223% above the low of $5.04 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $1.83 is for.
Which stocks are comparable to Personalis Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Personalis Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $16.28, calculated fair value $1.83 (−89%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PSNL calculated?
We run Personalis Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.83, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Personalis Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Personalis Inc (PSNL)?
The closing price on Oct 2, 2026 was $16.28. Our model-based fair value is $1.83, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Personalis Inc right now?
The price sits above even our optimistic bull case ($2.28). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.21 to $2.28) leaves room in how you read the outcome.
Key figures of Personalis Inc
How large is the market capitalisation of Personalis Inc (PSNL)?
The market capitalisation of Personalis Inc is $1.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Personalis Inc (PSNL)?
The price-to-sales ratio of Personalis Inc is 25.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Personalis Inc (PSNL)?
Earnings per share at Personalis Inc are $−1.10. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Personalis Inc (PSNL)?
The net margin of Personalis Inc is −117% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Personalis Inc (PSNL)?
The return on equity (ROE) of Personalis Inc is −50.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Personalis Inc (PSNL)?
On an EBIT basis the return on assets of Personalis Inc is −31.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Personalis Inc (PSNL)?
The operating margin of Personalis Inc is −150% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Personalis Inc (PSNL)?
Revenue at Personalis Inc is growing +30.0% versus a year earlier (3y avg +2.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Personalis Inc (PSNL) generate?
The free cash flow of Personalis Inc is −$79.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Personalis Inc (PSNL) hold?
Personalis Inc holds more cash than debt, $84.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Personalis Inc in the live analysis
One click puts Personalis Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026